Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Melissa Bedard, a PhD student in the Cerundolo lab at MRC HIU, writes for the Oxford University Science blog about cancer immunotherapy.

© NIH NIAID (CC BY 2.0)

October is a special time of year. The autumn leaves and crisp air mark the beginning of a new academic term. It also marks the annual announcements of the year’s Nobel Laureates, starting with the recipients of the Nobel Prize in Medicine and Physiology.

As scientists, we dream that our work today might revolutionise tomorrow – the kind of achievements that are recognised by a Nobel Prize. My research, like that of many immunologists, is primarily basic in nature. This year’s Nobel Prize in Medicine and Physiology is an exciting reminder that basic immunology discoveries can serve not only as key building blocks to better understanding fundamental immune cell function, but also as therapeutic targets in the fight against immune-mediated diseases.

Read the rest of the post on the Oxford University Science Blog.

Similar stories

New funding for early diagnosis research using platelets

MRC MHU RDM

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.

New study maps the development of the human intestine

MRC HIU RDM

Researchers in the Simmons lab chart the embryonic origins and appearance of diverse intestinal cellular compartments, with important implications for intestinal diseases.